



September 5, 2017

## **Anylam to Webcast Presentation at 15th Annual Morgan Stanley Global Healthcare Conference**

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Anylam Pharmaceuticals, Inc.](http://www.alnylam.com) (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the 15<sup>th</sup> Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2017 at 9:55 am ET at the Grand Hyatt in New York City.

A live audio webcast of the presentation will be available on the Investors section of the company's website, [www.alnylam.com](http://www.alnylam.com). A replay will be available on the Anylam website within 48 hours after the event.

### **About Anylam Pharmaceuticals**

Anylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases. Founded in 2002, Anylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are in late-stage development or will be in 2017. Looking forward, Anylam will continue to execute on its "Anylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines. For more information about our people, science and pipeline, please visit [www.alnylam.com](http://www.alnylam.com) and engage with us on Twitter at @Aanylam.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170905006287/en/>

### **Anylam Pharmaceuticals, Inc.**

Investors and Media  
Christine Regan Lindenboom, 617-682-4340  
or  
Investors  
Josh Brodsky, 617-551-8276

Source: Anylam Pharmaceuticals, Inc.

News Provided by Acquire Media